The synthesis and anticancer properties of 2-(4-amino-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-N-(5-R-benzylthiazol-2-yl)-acetamides
DOI:
https://doi.org/10.24959/ophcj.15.865Keywords:
2-aminothiazole, 1, 2, 4-triazole derivatives, chloroacetamides, arylation, Meerwein reaction, 4-amino-1, 4-triazole-3-thiole, anticancer activityAbstract
3-Aryl-2-chloropropanals 2a-h have been prepared by the reaction of arenediazonium chlorides 1a-h with acrolein in the conditions of Meerwein arylation (water-acetone, CuCl2 as a catalyst). These aldehydes react with thiourea by refluxing in ethanol to obtain 2-amino-5-R-benzyl-1,3-thiazoles 3a-h (R = 2-Cl, 3-Cl, 4-Cl, 3-CF3, 2,4-Cl2, 2,5-Cl2, 3,4-Cl2, 3-Cl-4-Me) with high yields. The resulting 2-aminothiazoles were acylated with chloroacetic acid chlorides to form 2-chloro-N-(5-aryl-1,3-thiazol-2-yl)acetamides 4a-h with the yields of 68-91%. By the reaction of compounds 4a-h with 4-amino-5-methyl-4H-1,2,4-triazole-3-thiole 5 a series of novel 2-(4-amino-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-N-(5-R-benzylthiazol-2-yl)-acetamides 6a-h (71-86%) have been synthesized. These compounds have been evaluated for their anticancer activity against 60 cancer lines in the concentration of 10 μM. The human tumour cell lines were derived from nine different cancer types: leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate, and breast cancers. Among all the derivatives, compounds 6a-c, 6e,f (R = 2-Cl, 3-Cl, 4-Cl, 2,4-Cl2, 2,5-Cl2) have been found to be active and have a high selectivity in relation to melanoma, while 2-(4-amino-5-methyl-4H-[1,2,4] triazol-3-ylsulfanyl)-N-[5-(2-chlorobenzyl)-thiazol-2-yl]-acetamide (6a) and 2-(4-amino-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-N-[5-(3,4-dichlorobenzyl)-thiazol-2-yl]-acetamide (6g) are active in relation to breast cancer.
Downloads
References
- Muller G. Drug Discov. Today, 2003, Vol. 8, pp.681-691. Doi: 10.1016/S1359-6446(03)02781-8.
- Mjambili F., Njoroge M., Naran K., De Kock C., Smith P. J., Mizrahi V., Warner D., Chibale K. Bioorg. Med. Chem. Lett., 2014, Vol. 24, pp.560-564. Doi: 10.1016/j.bmcl.2013.12.022.
- Makam P., Kannan Th. Eur. J. Med. Chem., 2014, Vol. 87, pp.643-656. Doi: 10.1016/j.ejmech.2014.09.086.
- Khalil A., Edwards J. A., Rappleye C. A., Tjarks W. Bioorg. Med. Chem., 2015, Vol. 23, pp.532-547. Doi:10.1016/j.bmc.2014.12.006.
- Pi Z., Sutton J., Lloyd J., Hua J., Price L., Wu Q., Chang M., Zheng J., Rehfuss R., Huang C. S., Wexler R. R., Lam P. Y. S. Bioorg. Med. Chem. Lett., 2013, Vol. 23, pp.4206-4209. Doi: 10.1016/j.bmcl.2013.05.025.
- Dicor A., Grand-Maоtre C., Hucke O., O’Meara J., Kuhn C. et al. Bioorg. Med. Chem. Lett., 2013, Vol. 23, pp.3841-3847. doi:10.1016/j.bmcl.2013.04.077.
- Mokale S. N., Elgire R. D., Sakle N., Shinde D. B. Bioorg. Med. Chem. Lett., 2011, Vol. 21, pp.682-685. Doi: 10.1016/j.bmcl.2010.12.011.
- Pattan S. R., Dighe N. S., Nirmal S. A. Merekar A. N., Musmade D. S., Laware R. B. Asian J. Research Chem., 2009, Vol. 2, pp.196-201.
- El-Subbagh H. I., El-Naccar W. A., Badria F. A. Qatar Univ. Sci. J., 1994, Vol. 14, pp.55-60.
- Kim K. S., Kimball S. D., Misra R. N., Rawlins D. B., Hunt J. T. et al. J. Med. Chem., 2002, Vol. 45, pp.3905-3927. Doi: 10.1021/jm0201520.
- El-Subbagh H. I., Abadi A. H., Lehmann J. Arch. Pharm. Med. Chem., 1999, Vol. 332, pp.137-142.
- Magd-El-Din A. A., Abd-El-All A. S., Roaiah M. F., El-Baroudy M. S. J. Am. Sci., 2010, Vol. 6(5), pp.251-256. Doi: 10.7537/j.issn. 1545-1003.
- Coe1 D., Armer R., Ratcliffe A. Drugs Future, 2009, Vol. 34, pp.247-254.
- Shao L., Zhou X., Hu Y., Jin Z., Liu J., Fang J. Synth. React. Inorg. Met.-Org. Chem., 2006, Vol. 36, pp.325-330. Doi: 10.1080/15533170600651405.
- Obushak N. D., Matiichuk V. S., Ganushchak N.I . Russ. J. Org. Chem. 1997. Vol. 33. No.7. pp.1010-1013 389 (English transl. from Zh. Org. Khim., 1997, Vol. 33, pp.1081-1083).
- Obushak N. D., Matiichuk V. S., Vasylyshin R.Ya., Ostapyuk Yu. V. Russ. J. Org. Chem. 2004, Vol. 40, рр.383-389 (English transl. from Zh. Org. Khim., 2004, Vol. 40, pp.412-417). Doi: 10.1023/B:RUJO.0000034976.75646.85.
- Boyd M. R., Paull K. D. Drug Dev. Res., 1995, Vol. 34, pp.91-109. Doi: 10.1002/ddr.430340203.
- Boyd M. R. In: Cancer Drug Discovery and Development. Teicher B. A., Ed.; Totowa, NJ, USA: Humana Press, 1997, Vol. 2, pp.23-43.
- Shoemaker R. H. Nat. Rev. Cancer, 2006, pp.813-823. Doi: 10.1038/nrc1951.
- Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M. J. Nat. Cancer. Inst., 1991, pp. 757-766. Doi: 10.1093/jnci/83.11.757.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:
1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.
3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).